Fusion polypeptide in which anti-inflammatory polypeptide and ferritin monomer fragment are bound and pharmaceutical composition for preventing and treating inflammatory diseases, containing same as active ingredient

US10513545B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10513545-B2
Application numberUS-201615757580-A
CountryUS
Kind codeB2
Filing dateSep 2, 2016
Priority dateSep 2, 2015
Publication dateDec 24, 2019
Grant dateDec 24, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to: a fusion polypeptide in which an anti-inflammatory polypeptide and a ferritin monomer fragment are bound; and a pharmaceutical composition for treating inflammatory diseases, containing the same as an active ingredient and, more specifically, to: a fusion polypeptide in which an anti-inflammatory polypeptide is fused to an N-terminus and/or a C-terminus of a ferritin monomer fragment from which a portion of a fourth loop and a fifth helix, of a human derived ferritin monomer, are removed; and a use thereof for treating inflammatory diseases. As in the above, the fusion polypeptide, which has an amino acid sequence represented by SEQ ID NO: 1 and in which an anti-inflammatory polypeptide is fused to an N-terminus and/or a C-terminus of a fragment of a human-derived ferritin monomer, can fuse two types of anti-inflammatory polypeptides, acting through different mechanisms, into a nano cage and administer the same, and thus the fusion polypeptide can exhibit an excellent effect in the treatment of inflammatory diseases including sepsis.

First claim

Opening claim text (preview).

What is claimed is: 1. A fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 15. 2. A polynucleotide encoding the fusion polypeptide of claim 1 . 3. An expression vector comprising the polynucleotide of claim 2 . 4. A transformant transformed with the expression vector of claim 3 . 5. A protein cage comprising the fusion polypeptide of claim 1 , wherein an anti-inflammatory polypeptide protrudes outside the protein cage. 6. A pharmaceutical composition, the composition comprising the fusion polypeptide of claim 1 as an active ingredient. 7. A method for treating an inflammatory disease in a subject in need thereof, the method comprising administering an effective amount of a composition comprising the fusion polypeptide of claim 1 as an active ingredient to the subject in need thereof. 8. The method of claim 7 , wherein the inflammatory disease is selected from the group consisting of inflammatory bowel disease, diabetic eye disease, peritonitis, osteomyelitis, cellulitis, meningitis, encephalitis, pancreatitis, traumatic shock, bronchial asthma, rhinitis, sinusitis, otitis, pneumonia, gastritis, enteritis, cystic fibrosis, apoplexy, bronchitis, bronchiolitis, hepatitis, nephritis, arthritis, gout, spondylitis, Reiter's syndrome, polyarteritis nodosa, irritable vasculitis, Lou Gehrig's granulomatosis, Polymyalgia rheumatica, arthritic arteritis, calcium crystal arthropathies, pseudogout, non-articular rheumatism, bursitis, tenosynovitis, epicondylitis (tennis elbow), neuropathic joint disease (Charcot's joint), hemarthrosis, Henoch-Schonlein purpura, hypertrophic osteoarthropathy, multicentric reticulohistiocytoma, surcoilosis, hemochromatosis, sickle cell disease and other hemochromatosis, hyperlipoproteinemia, hypogammaglobulinemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Behcet's disease, systemic lupus erythematosus, relapsing fever, psoriasis, multiple sclerosis, sepsis, septic shock, acute respiratory distress syndrome, multiple organ dysfunction syndrome, chronic obstructive pulmonary disease, acute lung injury and broncho-pulmonary dysplasia.

Assignees

Inventors

Classifications

  • IL-4 · CPC title

  • A61P29/00Primary

    Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

  • Transferrins, e.g. lactoferrins, ovotransferrins · CPC title

  • Transferrins, e.g. lactoferrins, ovotransferrins · CPC title

  • IL-4 · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10513545B2 cover?
The present invention relates to: a fusion polypeptide in which an anti-inflammatory polypeptide and a ferritin monomer fragment are bound; and a pharmaceutical composition for treating inflammatory diseases, containing the same as an active ingredient and, more specifically, to: a fusion polypeptide in which an anti-inflammatory polypeptide is fused to an N-terminus and/or a C-terminus of a fe…
Who is the assignee on this patent?
Kyungpook Nat Univ Ind Academic Coop Found, Korea Inst Sci & Tech
What technology area does this patent fall under?
Primary CPC classification A61P29/00. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).